Short description
Juno Therapeutics is a clinical-stage company, develops immunotherapies for the treatment of cancer.
Description
Juno is a clinical-stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute – in unique partnership to advance a broad pipeline of breakthrough immunotherapies. With one of the largest ever Series A investments for a biotech startup, Juno will build on the foundation of novel immunotherapies to develop two distinct and complementary platforms – CARs and TCRs.
Last funding
Noaccessforu
Sign in for full access
Total funding
$$2020202
Sign in for full access
Location
Seattle, Washington, United States, North America
Founded on
January 1, 2013
Exited on
December 19, 2014
Went public on
December 19, 2014
Delisted on
March 5, 2018
Stock symbol
JUNO
Non-profit?
No
Acquired?
No
Employees count
251-500
Revenue range
$56378 - 90123
Sign in for full access
Investors
Absolutely Noaccess, Noaccessforu, Absolutely Noaccess, Absolutely Noaccess
Sign in for full access
Founders
Hans Bishop, Isabelle Rivière, Michael Jensen, Michel Sadelain, Phil Greenberg, Renier Brentjens, Stan Riddell
Funding rounds count
3
Portfolio organisations count
Noaccessforu, Noaccessforu
Sign in for full access
Lead investments count
1
Exits count
Absolutely Noaccess, Noaccessforu
Sign in for full access
IPO exits count
2